Cardiac amyloidosis (CA) is a progressive infiltrative disease caused most commonly by the deposition of misfolded, cleaved and aggregated monoclonal immunoglobulin free light chain (AL) or transthyretin (ATTR) proteins in the myocardial extracellular space [1]. Recent advances in imaging techniques and the development of an algorithm for non-invasive confirmation of ATTR-CA [2] have transformed the diagnosis of this condition.
